Загрузка...
First-in-Human Randomized Trial to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of the KDM1A Inhibitor Vafidemstat
BACKGROUND: Vafidemstat, an inhibitor of the histone lysine-specific demethylase KDM1A, corrects cognition deficits and behavior alterations in rodent models. Here, we report the results from the first-in-human trial of vafidemstat in healthy young and older adult volunteers. A total of 110 voluntee...
Сохранить в:
| Опубликовано в: : | CNS Drugs |
|---|---|
| Главные авторы: | , , , , , , , , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
Springer International Publishing
2021
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7985749/ https://ncbi.nlm.nih.gov/pubmed/33755924 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40263-021-00797-x |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|